封面
市场调查报告书
商品编码
1447818

全球 mRNA 治疗市场规模、份额、成长分析,按类型(预防性疫苗、治疗性疫苗)、按应用(罕见遗传疾病、肿瘤)- 2024-2031 年产业预测

Global mRNA Therapeutics Market Size, Share, Growth Analysis, By Type(Prophylactic Vaccines, Therapeutic Vaccines), By Application(Rare Genetic Diseases, Oncology) - Industry Forecast 2024-2031

出版日期: | 出版商: SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格
简介目录

2022年全球MRNA治疗市场规模为408.0亿美元,预计将从2023年的416.2亿美元成长到2031年的487.6亿美元,预测期间(2024-2031年)CAGR为2%。

基于 mRNA 的疗法作为一种有效治疗慢性病的有前途的解决方案最近受到了极大的关注,从而导致市场的稳定和有保障的增长。近年来,mRNA疫苗因其在生产和分销方面的优势而比DNA疫苗受到青睐,提供了更安全的替代方案。这些疫苗和疗法已成功进行人体临床试验,进一步增加了对这些产品的需求。 Moderna 和 Pfizer-BioNTech 等公司在市场上发挥了重要作用,特别是在 COVID-19 大流行期间。他们为应对全球健康危机而开发的疫苗极大地推动了市场成长。 mRNA疗法也主要用于肿瘤临床试验,2021年针对癌症患者的mRNA疫苗试验吸引了大量志愿者,参与度排名第二,不包括针对癌症患者的COVID-19试验。自那时以来,该行业见证了显着的成长。全球范围内 SARS-CoV-2 病毒新变种的出现强调了对有效疫苗的需求,促使医疗专业人员转向 mRNA 疫苗。 COVID-19 大流行加速了基于 mRNA 的产品的利用,进一步推动了市场扩张。由于采用提高翻译和稳定性的技术进步以及递送技术,信使 RNA 已成为一种强大的治疗工具。製药业认识到 mRNA 疫苗的扩张潜力,显示该市场的成长前景广阔。 mRNA 疫苗代表了疫苗开发的下一个阶段,开创了免疫的新时代。一个很好的例子是Moderna Inc. 与美国国家过敏和传染病研究所之间的合作,最终于2020 年3 月创建了mRNA-1273 (NIAID)。 % 的有效率-19,于2020年12月获得美国FDA的快速批准和紧急使用授权。增加对基于mRNA的产品的需求未来。

目录

执行摘要

  • 市场概况
  • 命运之轮

研究方法论

  • 资讯采购
  • 二手和主要资料来源
  • 市场规模估计
  • 市场假设与限制

母公司市场分析

  • 市场概况
  • 市场规模
  • 市场动态
    • 司机
    • 机会
    • 限制
    • 挑战

主要市场洞察

  • 技术分析
  • 定价分析
  • 供应链分析
  • 价值链分析
  • 市场生态系统
  • 智慧财产权分析
  • 贸易分析
  • 启动分析
  • 原料分析
  • 创新矩阵
  • 管道产品分析
  • 总体经济指标
  • 顶级投资分析
  • 成功的关键因素
  • 竞争程度

市场动态与展望

  • 市场动态
    • 司机
    • 机会
    • 限制
    • 挑战
  • 监管环境
  • 波特分析
  • 对未来颠覆的特别见解

按类型分類的全球 mRNA 治疗市场

  • 市场概况
  • 预防性疫苗
  • 治疗性疫苗
  • 治疗药物

全球 mRNA 治疗市场(按应用)

  • 市场概况
  • 罕见遗传疾病
  • 肿瘤学
  • 呼吸疾病
  • 传染性疾病
  • 其他的

全球 mRNA 治疗市场规模(按地区)

  • 市场概况
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 德国
    • 西班牙
    • 法国
    • 英国
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 拉丁美洲
    • 巴西
    • 拉丁美洲其他地区
  • 中东和非洲 (MEA)
    • 海湾合作委员会国家
    • 南非
    • MEA 的其余部分

竞争格局

  • 前 5 名玩家比较
  • 2021 年关键参与者的市场定位
  • 主要市场参与者所采取的策略
  • 最佳制胜策略
  • 近期市集活动
  • 主要公司市占率(%),2021年

主要公司简介

  • CureVac AG (Germany)
  • Roche Holding AG (Switzerland)
  • Pfizer Inc. (USA)
  • GlaxoSmithKline plc (United Kingdom)
  • Moderna, Inc. (USA)
  • Sanofi SA (France)
  • BioNTech SE (Germany)
  • Dynavax Technologies Corporation (USA)
  • Arcturus Therapeutics Holdings Inc. (USA)
  • AstraZeneca plc (United Kingdom)
  • Regeneron Pharmaceuticals, Inc. (USA)
  • Alnylam Pharmaceuticals, Inc. (USA)
  • Gilead Sciences, Inc. (USA)
  • Mylan NV (USA)
  • Novartis AG (Switzerland)
  • Modulus Therapeutics, Inc. (USA)
  • Catalent, Inc. (USA)
  • Translate Bio, Inc. (USA)
  • Ionis Pharmaceuticals, Inc. (USA)
  • Vertex Pharmaceuticals Incorporated (USA)
简介目录
Product Code: SQMIG35A2547

Global MRNA Therapeutics Market size was valued at USD 40.80 Billion in 2022 and is poised to grow from USD 41.62 Billion in 2023 to USD 48.76 Billion by 2031, at a CAGR of 2% during the forecast period (2024-2031).

mRNA-based therapeutics have recently gained significant attention as a promising solution for effectively treating chronic conditions, leading to the steady and assured growth of the market. In recent times, mRNA vaccines have become preferred over DNA vaccines due to their advantages in production and distribution, offering a safer alternative. These vaccines and therapeutics have successfully undergone human clinical trials, further boosting demand for these products. Companies like Moderna and Pfizer-BioNTech have played a major role in the market, particularly during the COVID-19 pandemic. Their vaccines developed in response to the global health crisis significantly fueled market growth. mRNA therapeutics are also prominently used in oncology clinical trials, with mRNA vaccine trials for cancer patients in 2021 attracting a substantial number of volunteers, ranking second highest in participation, excluding COVID-19 trials in cancer patients. The industry has witnessed remarkable growth since then. The emergence of new variants of the SARS-CoV-2 virus worldwide has emphasized the need for effective vaccines, prompting medical professionals to turn to mRNA vaccines. The COVID-19 pandemic accelerated the utilization of mRNA-based products, further driving market expansion. Messenger RNA has emerged as a powerful therapeutic tool, thanks to technological advancements that improve translation and stability, as well as delivery techniques. The pharmaceutical industry recognizes the potential for expansion through mRNA vaccines, indicating promising growth prospects for the market. mRNA vaccines represent the next stage in vaccine development, ushering in a new era in immunization. An excellent example of this is the collaboration between Moderna Inc. and the National Institute of Allergy and Infectious Diseases, which resulted in the creation of mRNA-1273 (NIAID) in March 2020. This vaccine demonstrated a 94.1% efficacy rate in preventing symptomatic COVID-19, receiving expedited approval from the US FDA and emergency use authorization in December 2020. Furthermore, the rapidly expanding field of mRNA therapeutics is set to revolutionize personalized medicine, transforming traditional healthcare standards and increasing the demand for mRNA-based products in the foreseeable future.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global MRNA Therapeutics and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global MRNA Therapeutics Market Segmental Analysis

The global mRNA therapeutics market is segmented on the basis of type, application, region. By type, the market is segmented into prophylactic vaccines, therapeutic vaccines, therapeutic drugs. By application, the market is segmented into rare genetic diseases, oncology, respiratory diseases, infectious diseases, others. By end-use, the market is segmented into hospitals & clinics, research organizations, others. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global MRNA Therapeutics Market

The COVID-19 pandemic accelerated the development of mRNA vaccines, highlighting mRNA technology's effectiveness in fighting infectious diseases.

Growing investments from public and private sectors, such as government agencies and venture capital firms, are fuelling research and development (R&D) activities in mRNA therapies.

An increase in clinical trials for a range of illnesses, including cancer, rare genetic disorders, and infectious diseases, is driving the market's growth.

Restraints in the Global MRNA Therapeutics Market

The global market for mRNA therapeutics encountered several challenges, particularly in the production and distribution processes. Scaling up mRNA production capacity while maintaining a stable supply chain was notably challenging, especially during a global health crisis.

There are inherent risks in mRNA therapeutics, requiring extensive testing, experimentation, and analysis. Concerns arise regarding potential immune responses or off-target effects, which could pose safety risks in the future and potentially impede market growth.

The mRNA therapeutics market faces competition from emerging technologies and established treatments that offer similar benefits without the potential safety concerns. These alternative therapies pose a threat to the growth of the mRNA therapeutics market.

Market Trends of the Global MRNA Therapeutics Market

mRNA Cancer Vaccines: The market for mRNA cancer vaccines is experiencing a notable and impactful trend. The development of cancer vaccines using mRNA technology presents a significant opportunity for advancements in oncology treatment and therapy.

Partnerships and Collaborations: Another prevailing trend in the market and related industries is the increasing focus on mRNA product development and the rise in expertise within the field. This is largely due to the growing number of collaborations and mergers among global pharmaceutical companies.

Orphan Diseases: The market has also witnessed the emergence of a significant trend involving the treatment of rare diseases. The therapeutics offered by this market have the potential to address medical needs that have previously gone untreated, particularly in the realm of orphan diseases. As a result, mRNA therapies are gaining increased attention from medical professionals and patients alike.

Table of Contents

Executive Summary

  • Market Overview
  • Wheel of Fortune

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Parent Market Analysis

  • Market Overview
  • Market Size
  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges

Key Market Insights

  • Technology Analysis
  • Pricing Analysis
  • Supply Chain Analysis
  • Value Chain Analysis
  • Ecosystem of the Market
  • IP Analysis
  • Trade Analysis
  • Startup Analysis
  • Raw Material Analysis
  • Innovation Matrix
  • Pipeline Product Analysis
  • Macroeconomic Indicators
  • Top Investment Analysis
  • Key Success Factor
  • Degree of Competition

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Regulatory Landscape
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers
  • Skyquest Special Insights on Future Disruptions
    • Political Impact
    • Economic Impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Global mRNA Therapeutics Market by Type

  • Market Overview
  • Prophylactic Vaccines
  • Therapeutic Vaccines
  • Therapeutic Drugs

Global mRNA Therapeutics Market by Application

  • Market Overview
  • Rare Genetic Diseases
  • Oncology
  • Respiratory Diseases
  • Infectious Diseases
  • Others

Global mRNA Therapeutics Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • Spain
    • France
    • UK
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2021
  • Strategies Adopted by Key Market Players
  • Top Winning Strategies
    • By Development
    • By Company
    • By Year
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2021

Key Company Profiles

  • CureVac AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Roche Holding AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Pfizer Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GlaxoSmithKline plc (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Moderna, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanofi SA (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • BioNTech SE (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Dynavax Technologies Corporation (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Arcturus Therapeutics Holdings Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • AstraZeneca plc (United Kingdom)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Regeneron Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Alnylam Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Gilead Sciences, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Mylan N.V. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Novartis AG (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Modulus Therapeutics, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Catalent, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Translate Bio, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Ionis Pharmaceuticals, Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Vertex Pharmaceuticals Incorporated (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments